Inflammation triggers immune response to chronic viral infection

Washington D.C. [US], Oct. 23 (ANI): Scientists from the University of Basel discovered a fundamental new mechanism that helped in explaining the inadequate immune defense against chronic viral infection. The results may open up new avenues for vaccine development. In the course of an infection or upon vaccination, specialized cells of our immune system, so-called B cells, produce antibodies that bind viruses and inactivate them. In the context of chronic viral infections such as HIV or hepatitis C virus, however, antibody production by B cells is quantitatively inadequate and starts too late. A team of scientists headed by Daniel Pinschewer reported that the inadequate antibody response to chronic viral diseases is due to the strong inflammatory reaction upon infection. While most pronounced at the onset of an infection, inflammation can persist for decades, especially in HIV/AIDS. Hasty immune response lasts short-term: Under the influence of inflammatory messengers, so called interferons, B cells produce as many antibodies as they possibly can. Unfortunately, this hasty response occurs at the expense of sustainability. B cells that turn on antibody production too quickly lose their potential to proliferate and die shortly thereafter. As a consequence, the immune response takes an impetuous start but subsides rapidly. The scientists assume that this panic reaction of B cells reflects a mechanism ensuring an optimized response to acute life threatening infections. In the context of chronic infections, however, the battle is not decided within a matter of days but rather only after months or years. Under these circumstances, the hasty reaction of our body seems inappropriate and may actually favor the virus. Cornerstone for new vaccines: For viral diseases such as HIV or hepatitis C protective vaccines remain unavailable. The scientists are hopeful that the discovery of this fundamental mechanism may provide a basis to improve vaccination strategies against chronic viral diseases. The study was published in Immunol.1 journal. (ANI)